An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine

Autor: Thomas Wessel, Randall Kaye, Judy Caron, Gary Kay, Amy Halseth

Publikováno v: Journal of Clinical Pharmacy and Therapeutics

What is known and objective Tolperisone is a centrally acting muscle relaxant under development in the United States as a treatment for acute and painful symptoms of muscle spasms. The objective of this three‐way, randomized, blinded, three‐perio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b089e71a402321e60ed1e1bf01f405ea
https://doi.org/10.1111/jcpt.13165

Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study

Autor: Anna I. Guerdjikova, Kevin Shan, Susan L. McElroy, Eduardo Dunayevich, Amy Halseth, Brandon Walsh

Publikováno v: Advances in Therapy

Introduction Binge eating disorder (BED) is associated with obesity and major depressive disorder (MDD). Naltrexone extended-release (ER)/bupropion ER (NB) is approved as an adjunct to diet and physical activity for chronic weight management. In a pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9010fdec5c5550db098f8567cef96e5b
http://europepmc.org/articles/PMC5656719

Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity

Autor: Amy, Halseth, Kevin, Shan, Brandon, Walsh, Kye, Gilder, Ken, Fujioka

Publikováno v: Obesity (Silver Spring, Md.)

Objective This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks. Methods In this phase 3b, randomized,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a27e30f4b4d9b1376cc989edfd1d6d3b
https://pubmed.ncbi.nlm.nih.gov/28026920

Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea

Autor: Loretta L. Nielsen, Andrea Mari, Ralph A. DeFronzo, Eleuterio Ferrannini, Nuwan Nanayakkara, Amy Halseth

Publikováno v: Hormone and metabolic research 38 (2006): 838–844.
info:cnr-pdr/source/autori:Mari A., Nielsen L. L., Nanayakkara N., DeFronzo R. A., Ferrannini E., and Halseth A./titolo:Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea/doi:/rivista:Hormone and metabolic research/anno:2006/pagina_da:838/pagina_a:844/intervallo_pagine:838–844/volume:38

The incretin mimetic exenatide improved glycemic control and reduced body weight in patients with type 2 diabetes inadequately controlled with metformin+/-a sulfonylurea. We assessed postprandial beta-cell function by mathematical modeling, independe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ec4e0cd483154da2ad4a3700af19950
https://publications.cnr.it/doc/30345